The world's scientific and social network for malaria professionals
Subscribe to free Newsletter | 10907 malaria professionals are enjoying the free benefits of MalariaWorld today

drug resistnce

NOT Open Access | Tafenoquine is a Promising Drug Candidate for the Treatment of Babesiosis

May 5, 2021 - 11:28 -- NOT Open Access
Liu M, Ji S, Xuan X, et al.
Antimicrob Agents Chemother. 2021 May 3:AAC.00204-21

Due to drug resistance, commonly used anti-Babesia drugs have limited efficacy against babesiosis, and inflict severe side effects. Tafenoquine (TAF) was approved by the U.S. Food and Drug Administration in 2018 for the radical cure of Plasmodium vivax infection and for malaria prophylaxis. Here, we evaluated the efficacy of TAF for the treatment of Babesia infection and elucidated the suspected mechanisms of TAF activity against Babesia parasites. Parasitemia and survival rates of B. rodhaini-infected BALB/c and SCID mice were used to explore the role of the immune response in Babesia infection after TAF treatment.

Subscribe to RSS - drug resistnce